Open AccessOptimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China
Author(s) -
Xingbing Wu,
Can Huang,
Hui Wang,
Jinru Ji,
Ying Chen,
Yonghong Xiao
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s313714
Subject(s) - medicine , klebsiella pneumoniae , acinetobacter baumannii , polymyxin b , antimicrobial , renal function , carbapenem , antibiotics , microbiology and biotechnology , escherichia coli , biology , bacteria , biochemistry , genetics , pseudomonas aeruginosa , gene
Few pharmacodynamics studies to date have evaluated the efficacy and safety of polymyxin B (PMB) in treating patients with bloodstream infections (BSIs) in China.